Publications by authors named "Luigi Coltelli"

Claim this Profile
A
A Phase 2, Open Label, Multicenter, Single Arm Trial Evaluating the Activity and Safety of Abemaciclib + Aromatase Inhibitors (AIs) as Second-Line Treatment After First-Line Fulvestrant in Hormone-Receptor-Positive (HR+), Human-Epidermal-Growth-Factor-Receptor-Negative (HER2-) Metastatic Breast Cancer (MBC) Patients. Final Results of HERMIONE-7 Trial.
Cazzaniga Marina Elena, Pepe Francesca Fulvia, Rossi Emanuela, Coltelli Luigi, Beano Alessandra

Clin Breast Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of the axilla in breast cancer patients: critical review, regional modified Delphi consensus and implementation in the Tuscan breast network.
Matteo Ghilli, Carlotta Becherini, Icro Meattini, Catia Angiolini, Carmelo Bengala, Luigi Coltelli

Radiol Med· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-pegylated liposomal doxorubicin in older adjuvant early breast cancer patients: cardiac safety analysis and final results of the COLTONE study.
Luigi Coltelli, Chiara Finale, Gianna Musettini, Andrea Fontana, Maria Teresa Barletta

Clin Exp Med· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2- Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study.
Michelino De Laurentiis, Roberta Caputo, Manuelita Mazza, Mauro Mansutti, Riccardo Masetti, Luigi Coltelli

Target Oncol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Clinical Outcomes of Ribociclib in Combination with a Non-Steroidal Aromatase Inhibitor and a Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal HR+/HER2- Advanced Breast Cancer Patients: An Italian Managed Access Program.
Nicoletta Staropoli, Elena Geuna, Gaetana Rinaldi, Giancarlo Bisagni, Vieri Scotti, Luigi Coltelli

Curr Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients.
Luigi Coltelli, Giacomo Allegrini, Paola Orlandi, Chiara Finale, Andrea Fontana

NPJ Breast Cancer· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardioprotective Strategy for Patients With Nonmetastatic Breast Cancer Who Are Receiving an Anthracycline-Based Chemotherapy: A Randomized Clinical Trial.
Lorenzo Livi, Giuseppe Barletta, Francesca Martella, Calogero Saieva, Isacco Desideri, Luigi Coltelli

JAMA Oncol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE.
Silvana Leo, Ermenegildo Arnoldi, Lazzaro Repetto, Zaira Coccorullo, Saverio Cinieri, Luigi Coltelli

Oncologist· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial.
Chiara Cremolini, Carlotta Antoniotti, Sara Lonardi, Giuseppe Aprile, Francesca Bergamo, Luigi Coltelli

JAMA Oncol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiac safety of adjuvant non-pegylated liposomal doxorubicin combined with cyclophosphamide and followed by paclitaxel in older breast cancer patients.
Luigi Coltelli, Andrea Fontana, Sara Lucchesi, Laura Ginocchi, Guido Bocci

Breast· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic interaction of P2X7 receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients.
Anna Solini, Vittorio Simeon, Lisa Derosa, Paola Orlandi, Chiara Rossi, Luigi Coltelli

Oncotarget· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab.
Giacomo Allegrini, Luigi Coltelli, Paola Orlandi, Andrea Fontana, Andrea Camerini

Pharmacogenomics· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis.
Luigi Coltelli, Giacomo Allegrini, Paola Orlandi, Nicola Giuntini, Greta Alì

Pharmacogenomics· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pilot study of a day one and eight every three weeks administration of docetaxel in metastatic cancer patients.
Francesca Martella, Pier Giorgio Giannessi, Roberta Di Marsico, Luigi Coltelli, Valentina Safina

Tumori· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis